BioCryst has also filed its line extension application for the use of ORLADEYO oral granules in patients with HAE aged 2 to 11 years with the European Medicines Agency. Additional regulatory filings ...

Alkami Technology, Inc. ("Alkami"), a leading cloud-based digital banking solutions provider for financial institutions in the U.S., today announced that company executive leadership will present at ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present at the ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming ...

The FDA has accepted the New Drug Application for berotralstat as prophylactic therapy for pediatric patients aged 2 to 11 years with hereditary angioedema.

When an Omaha woman was diagnosed with a rare illness as a teenager, it affected not only her health but also her high school ...

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living ...

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Twenty-year old Noah Davis-Logan is a former national medalist in track, college student, and dedicated advocate for ...

Hereditary angioedema (HAE) is a potentially life-threatening genetic disorder characterized by recurrent swelling attacks.